In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models

Shock

Volumn 33, Issue 3, 2010, Pages 282-288

  Hagiwara, Satoshi ^a   Iwasaka, Hideo ^a   Matsumoto, Shigekiyo ^a   Hasegawa, Akira ^a   Yasuda, Norihisa ^a   Noguchi, Takayuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Acute lung injury; HMGB1; Inflammation; LPS; NF B; Thrombomodulin

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; RECOMBINANT THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTOXEMIA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG CONGESTION; LUNG EDEMA; LUNG HEMORRHAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN PHOSPHORYLATION; RAT; SEPSIS;

ACUTE LUNG INJURY; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; HMGB1 PROTEIN; I-KAPPA B KINASE; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; NF-KAPPA B; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; THROMBOMODULIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77149165099     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181b0ef7b     Document Type: Article

References (39)

1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Eng J Med 348:1546-1554, 2003.
2. Leaver SK, Evans TW: Acute respiratory distress syndrome. BMJ 335: 389-394, 2007.
3. Lehr HA, Bittinger F, Kirkpatrick CJ: Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy? J Pathol 190:373-386, 2000.
4. McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB: Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 12:R41, 2008.
5. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP: NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network: Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 33:1-6, 2005.
6. Mukhopadhyay S, Hoidal JR, Mukherjee TK: Role of TNFalpha in pulmonary pathophysiology. Respir Res 7:125, 2006.
7. Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19:5237-5246, 1999.
8. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164:1768-1773, 2001.
9. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126:389-392, 1999.
10. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61:1-9, 2005.
11. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H: Hmgb1 signals through Toll-like receptor (Tlr) 4 and Tlr2. Shock 26:174-179, 2006.
12. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251, 1999.
13. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, et al.: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170:1310-1316, 2004.
14. Dittman WA, Majerus PW: Structure and function of thrombomodulin: a natural anticoagulant. Blood 75:329-336, 1990.
15. Levi M, van der Poll T: Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 11(suppl 5):S3, 2007.
16. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 86:51-56, 2001.
17. Dahlback B, Villoutreix BO: The anticoagulant protein C pathway. FEBS Lett 579:3310-3316, 2005.
18. Freeman BD, Zehnbauer BA, Buchman TG: A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 20:5-9, 2003.
19. Matthay MA: Severe sepsis: a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med 344:759-762, 2001.
20. Esmon C, Owen W: Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78:2249-2252, 1981. (Pubitemid 11119893)
21. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, et al.: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18:236-241, 2002.
22. Bastarache JA, Ware LB, Bernard GR: The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 27:365-376, 2006.
23. Ware LB, Fang X, Matthay MA: Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 285:L514-L521, 2003.
24. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT: The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 93: 10212-10216, 1996. (Pubitemid 26314601)
25. Bhatia M, Moochhala S: Role of inflammatory mediators in the pathophysi-ology of acute respiratory distress syndrome. J Pathol 202:145-156, 2004.
26. Strieter RM, Kunkel SL, Bone RC: Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21:S447-S463, 1993.
27. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six: at six interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467, 2002.
28. Wang H, Yang H, Tracey KJ: Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255:320-331, 2004.
29. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ: HMG-1 as a mediator of acute lung inflammation. J Immunol 165:2950-2954, 2000.
30. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, et al.: The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiin-flammatory mechanism. J Clin Invest 115:1267-1274, 2005.
31. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, Choe KH, Strassheim D, Pitts TM, Tracey KJ, et al.: Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 284:C870-C879, 2003.
32. Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725-734, 2002.
33. Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290: 622-645, 2006.
34. Zingarelli B, Sheehan M, Wong HR: Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 31:105-111, 2003.
35. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, et al.: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 196:565-577, 2002.
36. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 13:85-94, 2001.
37. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG: Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 315:1188-1195, 2005.
38. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr: Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868-31874, 1999.
39. Remick DG, Ward PA: Evaluation of endotoxin models for the study of sepsis. Shock 24(suppl 1):7-11, 2005.